These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 29946775)
1. The Multifaceted Metabolism of Glioblastoma. Quinones A; Le A Adv Exp Med Biol; 2018; 1063():59-72. PubMed ID: 29946775 [TBL] [Abstract][Full Text] [Related]
2. The Multifaceted Glioblastoma: From Genomic Alterations to Metabolic Adaptations. Quinones A; Le A Adv Exp Med Biol; 2021; 1311():59-76. PubMed ID: 34014534 [TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes. Patil V; Mahalingam K Gene; 2019 Feb; 685():85-95. PubMed ID: 30401645 [TBL] [Abstract][Full Text] [Related]
4. Glioblastoma multiforme: Metabolic differences to peritumoral tissue and IDH-mutated gliomas revealed by mass spectrometry imaging. Kampa JM; Kellner U; Marsching C; Ramallo Guevara C; Knappe UJ; Sahin M; Giampà M; Niehaus K; Bednarz H Neuropathology; 2020 Dec; 40(6):546-558. PubMed ID: 32662157 [TBL] [Abstract][Full Text] [Related]
5. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma. Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920 [TBL] [Abstract][Full Text] [Related]
6. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme. Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071 [TBL] [Abstract][Full Text] [Related]
7. Glioblastoma: pathology, molecular mechanisms and markers. Aldape K; Zadeh G; Mansouri S; Reifenberger G; von Deimling A Acta Neuropathol; 2015 Jun; 129(6):829-48. PubMed ID: 25943888 [TBL] [Abstract][Full Text] [Related]
8. Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review. Anjum K; Shagufta BI; Abbas SQ; Patel S; Khan I; Shah SAA; Akhter N; Hassan SSU Biomed Pharmacother; 2017 Aug; 92():681-689. PubMed ID: 28582760 [TBL] [Abstract][Full Text] [Related]
9. Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. Mineo JF; Bordron A; Baroncini M; Maurage CA; Ramirez C; Siminski RM; Berthou C; Dam Hieu P J Neurooncol; 2007 Dec; 85(3):281-7. PubMed ID: 17571214 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells. Petővári G; Dankó T; Krencz I; Hujber Z; Rajnai H; Vetlényi E; Raffay R; Pápay J; Jeney A; Sebestyén A Pathol Oncol Res; 2020 Jan; 26(1):23-33. PubMed ID: 31187466 [TBL] [Abstract][Full Text] [Related]
11. Overview of Transforming Growth Factor β Superfamily Involvement in Glioblastoma Initiation and Progression. Nana AW; Yang PM; Lin HY Asian Pac J Cancer Prev; 2015; 16(16):6813-23. PubMed ID: 26514451 [TBL] [Abstract][Full Text] [Related]
12. The Glioblastoma Microenvironment: Morphology, Metabolism, and Molecular Signature of Glial Dynamics to Discover Metabolic Rewiring Sequence. Virtuoso A; Giovannoni R; De Luca C; Gargano F; Cerasuolo M; Maggio N; Lavitrano M; Papa M Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33804873 [TBL] [Abstract][Full Text] [Related]
16. Molecular and Genomic Alterations in Glioblastoma Multiforme. Crespo I; Vital AL; Gonzalez-Tablas M; Patino Mdel C; Otero A; Lopes MC; de Oliveira C; Domingues P; Orfao A; Tabernero MD Am J Pathol; 2015 Jul; 185(7):1820-33. PubMed ID: 25976245 [TBL] [Abstract][Full Text] [Related]
17. Metabolic Reprogramming in Glioblastoma Multiforme: A Review of Pathways and Therapeutic Targets. Cortes Ballen AI; Amosu M; Ravinder S; Chan J; Derin E; Slika H; Tyler B Cells; 2024 Sep; 13(18):. PubMed ID: 39329757 [TBL] [Abstract][Full Text] [Related]
18. Ccl5 establishes an autocrine high-grade glioma growth regulatory circuit critical for mesenchymal glioblastoma survival. Pan Y; Smithson LJ; Ma Y; Hambardzumyan D; Gutmann DH Oncotarget; 2017 May; 8(20):32977-32989. PubMed ID: 28380429 [TBL] [Abstract][Full Text] [Related]
19. Metabolic therapy: a new paradigm for managing malignant brain cancer. Seyfried TN; Flores R; Poff AM; D'Agostino DP; Mukherjee P Cancer Lett; 2015 Jan; 356(2 Pt A):289-300. PubMed ID: 25069036 [TBL] [Abstract][Full Text] [Related]
20. MiR-181b modulates EGFR-dependent VCAM-1 expression and monocyte adhesion in glioblastoma. Liu YS; Lin HY; Lai SW; Huang CY; Huang BR; Chen PY; Wei KC; Lu DY Oncogene; 2017 Aug; 36(35):5006-5022. PubMed ID: 28459461 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]